Granite Investment Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Granite Investment Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$401K	Buy	5,345 +539	+11%	+$42.5K	0.02%	200
2025 Q4	$380K	Sell	4,806 -23,227	-83%	-$1.75M	0.02%	202
2025 Q3	$1.83M	Sell	28,033 -15,148	-35%	-$740K	0.1%	164
2025 Q2	$1.71M	Sell	43,181 -25,253	-37%	-$826K	0.08%	185
2025 Q1	$2.06M	Sell	68,434 -5,432	-7%	-$178K	0.1%	182
2024 Q4	$2.58M	Sell	73,866 -11,927	-14%	-$446K	0.11%	176
2024 Q3	$3.44M	Sell	85,793 -28,297	-25%	-$1.32M	0.15%	163
2024 Q2	$5.44M	Sell	114,090 -2,054	-2%	-$84.2K	0.23%	138
2024 Q1	$5.03M	Sell	116,144 -3,802	-3%	-$181K	0.19%	149
2023 Q4	$6.07M	Buy	+119,946	New	+$5.75M	0.24%	124

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Granite Investment Partners's IONS Position: Q1 2026 in Review

Granite Investment Partners increased its Ionis Pharmaceuticals (IONS) stake by 11% in Q1 2026, buying an estimated $42.5K and bringing the position to 5,345 shares worth $401K. The position accounts for 0.02% of the portfolio, ranked #200.

Granite Investment Partners first reported a position in IONS in Q4 2023 and has held it in 10 quarters since. The position peaked at $6.07M in Q4 2023. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Granite Investment Partners held 5,345 shares of Ionis Pharmaceuticals worth $401K as of Q1 2026.
Granite Investment Partners bought 539 Ionis Pharmaceuticals shares in Q1 2026, an estimated $42.5K.
Ionis Pharmaceuticals made up 0.02% of Granite Investment Partners's portfolio in Q1 2026, its #200 holding.
Granite Investment Partners first reported a position in Ionis Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Granite Investment Partners's Ionis Pharmaceuticals position peaked at $6.07M in Q4 2023.
494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Granite Investment Partners's 13F filing for Q1 2026, filed 30 Apr 2026.